Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

This study evaluated how plozasiran, a newly approved RNA interference (RNAi) therapy, lowers harmful triglyceride (TG) levels in patients with familial chylomicronemia syndrome (FCS), a rare genetic disease associated with dangerously high triglycerides and a high risk of acute pancreatitis.

Researchers used population pharmacodynamic (PD) modeling to better understand how the drug works in the body and how it affects levels of apolipoprotein C-III (APOC3), a protein that plays a key role in regulating triglycerides. The analysis showed that plozasiran effectively blocks APOC3 production in the liver, leading to substantial reductions in triglyceride levels.

The modeling demonstrated that plozasiran has strong and durable activity, with effects lasting long enough to support convenient once every 3 months dosing. The study also found that factors such as body mass index (BMI), ethnicity, and mild kidney or liver impairment did not meaningfully impact treatment response, supporting use of the same 25 mg dose across a broad adult patient population.

Importantly, the results showed that plozasiran was similarly effective in both genetically confirmed and clinically diagnosed FCS patients, helping support broader use of the therapy in real-world clinical practice.

Overall, this work highlights how model informed drug development and pharmacodynamic modeling can help optimize dosing strategies, support regulatory decision making, and improve treatment approaches for patients with rare diseases.